Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

10 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic leukemia

ABSTRACT: Gene expression study of shRNA knockdown of GATA1 in the megakaryoblastic cell line Meg01. Cell culture samples from two Meg01 clones (GATA1 4-14 and GATA1 5-13) were compared against a negative control infection sample (GATA1-neg). Two dye-swap microarrays were completed for each clone.

ORGANISM(S): Homo sapiens

SUBMITTER: Yubin Ge

PROVIDER: E-GEOD-42879 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

The unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy

Project description:Microarray gene expression profiling of lentivirus shRNA knockdown of the GATA1 gene in a DS AMkL cell line, CMK (harbors a mutated GATA1 gene and only expresses GATA1s). Cell culture samples from two CMK clones (CMK-5a and CMK-5b) were compared against a negative control infection sample (CMK-neg). Two dye-swap microarrays were completed for each clone.

2012-05-31 | E-GEOD-32388 | biostudies-arrayexpress

Identification of GATA1 transcriptional regulation in the megakaryoblastic cell line Meg01

Project description:chIP-on-chip analysis of GATA1 in the megakaryoblastic cell line Meg01. The IP was obtained with a GATA1 C-terminus antibody. The control sample was a normal goat IgG pull down done side by side with the GATA1 (C-20) antibody using the same soluble chromatin sample from non-treated Meg-01 cells. A 2-chip microarray set (Agilent 240K) was used for the chIP-on-chip analysis.

2013-07-01 | E-GEOD-43018 | biostudies-arrayexpress

Runx1 (Aml1) knockdown in AMkL Meg-01 cells

Project description:Transcriptional profiling of the effect of shRNA silencing of Runx1 in human AMkL Meg-01 cells. RNA samples obtained from two independent colonies were compared to RNAs from negative control transductions in a two-color design. A total of four microarrays were completed, with a dye-swapped pair performed for each colony. Two-condition experiment, Runx1 knockdown vs. negative transduction controls. Biological replicates: 2 knockdown replicates, 2 control replicates.

2009-08-01 | E-GEOD-17311 | biostudies-arrayexpress

Gene expression signature of MYB-GATA overexpression plus GATA1 down regulation in undifferentiated or differentiated UT7 cells

Project description:Acute basophilic leukemia is a rare subtype of acute myeloblastic leukemia. We recently described a recurrent t(X;6)(p11;q23) translocation occurring in male infants with acute basophilic leukemia, generating a MYB-GATA1 fusion gene. To better understand the role of MYB-GATA1 in the leukemogenesis of acute basophilic leukemias, we expressed this chimeric transcription factor in the UT-7 cell line under normal or differentiating conditions. A gene expression analysis revealed 9 genes deregulated by both MYB-GATA1 and the basophilic differentiation. Three of these genes (CCL23, IL1RL1 and NTRK1) were also increased by MYB-GATA1 in CD34-positive cells, as indicated by quantitative RT-PCR. Two independant experiments (A and S) were performed. For each experiment, UT7 cells were transduced with two lentivirus: a lentivirus carrying the MYB-GATA1 (or a control) coding sequence, and a lentivirus carrying a GATA1 (or control) shRNA. Cells transduced with both lentiviruses were selected, and kept in culture under standard or differentiating conditions for 7 days before RNA extraction.

2016-09-01 | E-GEOD-72913 | biostudies-arrayexpress

Role of trisomy 21, GATAs mutation and associated mutations in the development of a DS-AMKL model from IPSC: Cut&Tag

Project description:Acute megakaryoblastic leukemia of Down syndrome (DS-AMKL) is a model of clonal evolution from a preleukemic transient myeloproliferative disorder requiring both a trisomy 21 (T21) and a GATA1s mutation to a leukemia driven by additional driver mutations. We modelled this leukemic evolution through stepwise gene editing of GATA1s, SMC3+/- and MPLW515K providing 20 different trisomy or disomy 21 iPSC clones. Cut&Tag against GATA1 was performed on CD41+CD42+ megakaryocytes obtained after 18 days of differentiation of the IPSC clones. 500,000 CD41+CD42+ MK sorted cells were used to analyze GATA1 and GATA1s chromatin occupancy using the CUT&Tag-IT Assay Kit (Active Motif) according to the manufacturer recommendations. Briefly, cells were bound to Concanavalin A-Coated Beads and incubated with primary anti-GATA1 antibody in buffer with Protease Inhibitor Cocktail and 5% digitonine overnight at 4°C under rotation. The Guinea Pig anti-rabbit secondary antibody was incubated in Dig-Wash buffer for 1 hour at RT under rotation. After 3 washes, the CUT&Tag-IT™ Assembled pA-Tn5 Transposomes (1:100) were added for 1 hour at RT under rotation and tagmentation was performed during 1 hour at 37°C. DNA was purified and libraries were generated by PCR. The final libraries were purified, pooled together in equal concentrations and subjected to paired-end sequencing (100 cycles: 2x50) in Novaseq-6000 sequencer (Illumina) at Gustave Roussy.

2022-09-30 | E-MTAB-11032 | biostudies-arrayexpress

Identification of GATA1 transcriptional regulation in the megakaryoblastic cell line Meg01

Project description:chIP-on-chip analysis of GATA1 in the megakaryoblastic cell line Meg01.

2013-07-01 | GSE43018 | GEO

Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic leukemia

Project description:Gene expression study of shRNA knockdown of GATA1 in the megakaryoblastic cell line Meg01.

2013-07-01 | GSE42879 | GEO

Human tongue squamous cell carcinoma cell line SAS-Control vs. SAS-LYRIC knockdown stable clones global gene profiling

Project description:Transcriptional profiling of SAS cells transfected with pLKO.1-LYRIC shRNA-B expression vector (desinaged as B) and control SAS cells (transfected with pLKO.1 vector, designated as CTL). Goal was to determine the effects of LYRIC knockdown on global SAS cells gene expression. Two-condition experiment, SAS cells transfected with pLKO.1-LYRIC shRNA-B expression vector (desinaged as B) v.s. control SAS cells (transfected with pLKO.1 vector, designated as CTL). Biological replicates: 4 control replicates, 4 transfected replicates.

2016-02-28 | E-GEOD-44766 | biostudies-arrayexpress

Consequences of GATA1 expression in Gata1- G1ME Murine Megakaryocyte/Erythrocyte Progenitor Cell Line

Project description:G1ME cells are GATA1-deficient murine bipotential megakaryocyte/erythrocyte progenitor cells derived from Gata1-negative murine ES cells. In order to assess the impact of GATA1 on gene regulation and cell differentiation, an expression construct was used to transiently produce high levels of GATA1. Cells transduced with this construct or a vector control were harvested at 18 and 42 hours, and gene expression was analyzed using Affymetrix MOE430 version 2 arrays. Both vector control and GATA1-expressing cells were isolated by FACS for GFP and 18 and 42 hours. Biologic triplicates were performed for each construct at each timepoint.

2009-06-10 | E-GEOD-14980 | biostudies-arrayexpress

Multiplexed DNA high throughput genotyping study to determine the mutational status of transient (TAM) and acute myeloid leukaemic (ML-DS) Down syndrome individuals.

Project description:We used a 48.48 Fluidigm Access Array approach (1070 Amplicons spanning 62 genes: 157kB coverage) of genomic DNA from over 100 samples to genotype individuals with transient abnormal myelopoiesis (TAM) and acute myeloid leukemia of Down syndrome (ML-DS). Individually barcoded patient samples were subjected to paired-end 150bp sequencing (Illumina MiSeq), including paired GATA1 variant negative controls (including Post treatment) and 8 known reference GATA1- controls. Samples were mapped to build 37 of the human reference genome and subject to bioinformatic analysis (Varscan, Pindel, GATK) to facilitate the characterisation of known gene mutations in cancer as well as the identification / validation of potentially novel variants.

2019-07-17 | E-MTAB-7729 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data